Document is current
Any future updates will be listed below
-
Authors
Daws, Richard E. https://orcid.org/0000-0002-6639-5768
Timmermann, Christopher
Giribaldi, Bruna
Sexton, James D. https://orcid.org/0000-0002-3402-2748
Wall, Matthew B.
Erritzoe, David
Roseman, Leor
Nutt, David https://orcid.org/0000-0002-1286-1401
Carhart-Harris, Robin
-
Funding
Funding for this research was provided by:
RCUK | Engineering and Physical Sciences Research Council (EP/L016737/1)
RCUK | Medical Research Council (MR/J00460X/1, MR/J00460X/1)
- License Information
-
More Information
Article History
Received: 10 May 2021
Accepted: 14 February 2022
First Online: 11 April 2022
Competing interests
: R.C.H. reports receiving consulting fees from Entheon Biomedical and Beckley Psytech; B.G. received consulting fees from SmallPharma; D.E. received consulting fees from Field Trip and Mydecine; D.N. received consulting fees from Algernon and H. Lundbeck and Beckley Psytech, advisory board fees from COMPASS Pathways and lecture fees from Takeda and Otsuka and Janssen plus owns stock in Alcarelle, Awakn and Psyched Wellness. The other authors declare no competing interests.
